Choose Your Language

English Spanish

Investment case

  • Global leader in the c.£200bn consumer healthcare market1 which is underpinned by long term structural tailwinds and resilient categories
  • Portfolio of Superior Brands which are rooted in Trusted Science which outperform through our leading route to market capabilities
  • Significant headroom for growth in addressing incidence vs treatment penetration, innovation led premiumisation and expanding reach to low-income consumers
  • As a standalone company, we are driving a step change in our supply chain which will drive £800m in gross cost savings over the next five years
  • Compelling financial algorithm of 4-6% annual organic revenue growth3 and high-single digit adjusted operating profit3 growth at constant currency enabling strong EPS4 growth
  • Strong free cash generation allowing disciplined capital allocation resulting in industry-leading shareholder returns

 

Factsheet

2025 Half Year Results with our CEO and CFO

Updates

For the most up to date information on financial performance, shareholder services and more information.

Regulatory news

Behind our brands with Investor Relations

While Haleon may be a relatively new name, many of our brands have been loved and trusted for generations. Join the Investor Relations team as we deep dive into some of these brands; showcasing their history and innovation. 

 

 

Panadol

A trusted global brand powered by science and deep human understanding. For generations, Panadol has been providing relief and care, making it a staple in homes around the world.

Contact information

If you are an institutional shareholder or equity analyst and would like information on Haleon, please contact our investor relations team.

Investor Relations contacts

1 Nicholas Hall (VMS,OTC) and Global Data (Oral Health) 2024

3 See FY 2024 Annual Report for definitions

4 Refers to adjusted EPS; see FY 2024 Annual report for definitions